Fibrates for the Treatment of Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid: An Exploratory Study

Up to 40% of patients with primary biliary cholangitis (PBC) will have a suboptimal biochemical response to ursodeoxycholic acid (UDCA), which can be improved by the addition of fibrates. This exploratory study aims to evaluate the long-term real-life biochemical response of different fibrates, including ciprofibrate, in subjects with UDCA-unresponsive PBC. The Brazilian Cholestasis Study Group multicenter database was reviewed to assess the response rates to UDCA plus fibrates in patients with UDCA-unresponsive PBC 1 and 2 years after treatment initiation by different validated criteria. In total, 27 patients (100% women, mean age 48.9 ± 9.2 years) with PBC were included. Overall response rates to fibrates by each validated criterion varied from 39 to 60% and 39-76% at 12 and 24 months after treatment combination, respectively. Combination therapy resulted in a significant decrease in ALT and ALP only after 2 years, while GGT significantly improved in the first year of treatment. Treatment response rates at 1 and 2 years appear to be comparable between ciprofibrate and bezafibrate using all available criteria. Our findings endorse the efficacy of fibrate add-on treatment in PBC patients with suboptimal response to UDCA. Ciprofibrate appears to be at least as effective as bezafibrate and should be assessed in large clinical trials as a possibly new, cheaper, and promising option for treatment of UDCA-unresponsive PBC patients.

Citing Articles

Efficacy and safety of fenofibrate add-on therapy in patients with primary biliary cholangitis refractory to ursodeoxycholic acid: A retrospective study and updated meta-analysis.

Guoyun X, Dawei D, Ning L, Yinan H, FangFang Y, Siyuan T Front Pharmacol. 2022; 13:948362.

PMID: 36110537 PMC: 9468667. DOI: 10.3389/fphar.2022.948362.

Gene Therapy for Acquired and Genetic Cholestasis.

Martinez-Garcia J, Molina A, Gonzalez-Aseguinolaza G, Weber N, Smerdou C Biomedicines. 2022; 10(6).

PMID: 35740260 PMC: 9220166. DOI: 10.3390/biomedicines10061238.

References

Monroy-Ramirez H, Galicia-Moreno M, Sandoval-Rodriguez A, Meza-Rios A, Santos A, Armendariz-Borunda J . PPARs as Metabolic Sensors and Therapeutic Targets in Liver Diseases. Int J Mol Sci. 2021; 22(15). PMC: 8347792. DOI: 10.3390/ijms22158298. View

Montano-Loza A, Corpechot C . Definition and Management of Patients With Primary Biliary Cholangitis and an Incomplete Response to Therapy. Clin Gastroenterol Hepatol. 2020; 19(11):2241-2251.e1. DOI: 10.1016/j.cgh.2020.06.062. View

Ghonem N, Assis D, Boyer J . Fibrates and cholestasis. Hepatology. 2015; 62(2):635-43. PMC: 4515188. DOI: 10.1002/hep.27744. View

Grigorian A, Mardini H, Corpechot C, Poupon R, Levy C . Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: A meta-analysis. Clin Res Hepatol Gastroenterol. 2015; 39(3):296-306. DOI: 10.1016/j.clinre.2015.02.011. View

Carrion A, Lindor K, Levy C . Safety of fibrates in cholestatic liver diseases. Liver Int. 2021; 41(6):1335-1343. DOI: 10.1111/liv.14871. View

Harms M, van Buuren H, Corpechot C, Thorburn D, Janssen H, Lindor K . Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. J Hepatol. 2019; 71(2):357-365. DOI: 10.1016/j.jhep.2019.04.001. View

Ghonem N, Boyer J . Fibrates as adjuvant therapy for chronic cholestatic liver disease: its time has come. Hepatology. 2012; 57(5):1691-3. PMC: 4048949. DOI: 10.1002/hep.26155. View

Lleo A, Wang G, Gershwin M, Hirschfield G . Primary biliary cholangitis. Lancet. 2020; 396(10266):1915-1926. DOI: 10.1016/S0140-6736(20)31607-X. View

Tanaka N, Aoyama T, Kimura S, Gonzalez F . Targeting nuclear receptors for the treatment of fatty liver disease. Pharmacol Ther. 2017; 179:142-157. PMC: 6659998. DOI: 10.1016/j.pharmthera.2017.05.011. View

10.

Cheung A, Lapointe-Shaw L, Kowgier M, Meza-Cardona J, Hirschfield G, Janssen H . Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes. Aliment Pharmacol Ther. 2015; 43(2):283-93. DOI: 10.1111/apt.13465. View

11.

Betteridge D, OBryan-Tear C . Comparative efficacy and safety of ciprofibrate and sustained-release bezafibrate in patients with type II hyperlipidaemia. Postgrad Med J. 1996; 72(854):739-43. PMC: 2398656. DOI: 10.1136/pgmj.72.854.739. View

12.

Nakai S, Masaki T, Kurokohchi K, Deguchi A, Nishioka M . Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study. Am J Gastroenterol. 2000; 95(1):326-7. DOI: 10.1111/j.1572-0241.2000.01667.x. View

13.

Tanaka A, Hirohara J, Nakano T, Matsumoto K, Chazouilleres O, Takikawa H . Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis. J Hepatol. 2021; 75(3):565-571. DOI: 10.1016/j.jhep.2021.04.010. View

14.

Lindor K, Bowlus C, Boyer J, Levy C, Mayo M . Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018; 69(1):394-419. DOI: 10.1002/hep.30145. View

15.

Corpechot C, Chazouilleres O, Rousseau A, Le Gruyer A, Habersetzer F, Mathurin P . A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. N Engl J Med. 2018; 378(23):2171-2181. DOI: 10.1056/NEJMoa1714519. View

16.

Cancado G, Braga M, Ferraz M, Villela-Nogueira C, Terrabuio D, Cancado E . Clinical features and treatment outcomes of primary biliary cholangitis in a highly admixed population. Ann Hepatol. 2021; 27(1):100546. DOI: 10.1016/j.aohep.2021.100546. View

17.

Itakura J, Izumi N, Nishimura Y, Inoue K, Ueda K, Nakanishi H . Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis. Hepatol Res. 2004; 29(4):216-222. DOI: 10.1016/j.hepres.2004.04.001. View

18.

Joshita S, Umemura T, Yamashita Y, Sugiura A, Yamazaki T, Fujimori N . Biochemical and plasma lipid responses to pemafibrate in patients with primary biliary cholangitis. Hepatol Res. 2019; 49(10):1236-1243. DOI: 10.1111/hepr.13361. View

19.

de Vries E, Bolier R, Goet J, Pares A, Verbeek J, de Vree M . Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial. Gastroenterology. 2020; 160(3):734-743.e6. DOI: 10.1053/j.gastro.2020.10.001. View

20.

Reig A, Sese P, Pares A . Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response. Am J Gastroenterol. 2017; 113(1):49-55. DOI: 10.1038/ajg.2017.287. View